hotspot -WSS

hotspot

author：hotspot 2025-09-03 05:29:09 - browse：42425

Illumina said Monday afternoon that its board of directors had approved a spin-off of its cancer test subsidiary Grail, signaling that a nearly four-year-long, $8 billion saga will finally draw to a close this month.

Shares in the newly independent Grail are expected to be distributed on June 24, Illumina said in a statement. Illumina will retain a 14.5% stake in the company, which will trade under the ticker $GRAL.

It’s the second time Illumina has spun off Grail, which initially began as a unit within the DNA sequencing giant in 2015. Illumina turned it into an independent company the following year but then agreed to reacquire it for $8 billion in September 2020.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： White House touts steps to stem shortages of cancer treatments

WSS

Awakening the world to the whoosh: A patient's crusade

Tesla recalling nearly 16,000 of its 2021

Hospitals consider fixing cancer drug shortages on their own

White House touts steps to stem shortages of cancer treatments

Hospitals consider fixing cancer drug shortages on their own

Ending racial health disparities hinges on penalties, political will

focus

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Anesthesiologist group: stop taking Ozempic before surgery

A common UTI test for kids haunts adults as a traumatic 'nightmare'

Supreme Court strikes down use of affirmative action

What to make of Biden’s latest efforts on cancer research

ChatGPT in medicine: STAT answers readers' burning questions

WATCH: Why do bright lights make us see spots?

State Dept. review finds Biden bears some blame for Afghanistan failures

Senate committee advances SCOTUS ethics bill after alleged justice misconduct

The high cost of giving birth even with insurance

Acelyrin, a rare IPO success, stumbles in its first big test

explore

EF3 tornado rips through North Carolina amid extreme weather nationwide

Wildfires rage amid heat wave in Greece, prompting evacuations and call for European support

Senate committee advances SCOTUS ethics bill after alleged justice misconduct

Texas Department of Public Safety speaks out on migrant abuse allegations

Indian pharmaceutical industry in denial over drug

Private equity could exacerbate cardiology's overuse problem, experts fear

hotspot

leisure time

hotspot

focus